Project Grant R01AR087343
Award Date 9/4/26
Completion Date 5/31/31
Dollars Obligated $473K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The Trustees of the University of Pennsylvania $546,145 on May 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate molecular mechanisms of telomere function in muscle cells. The research will determine the extra-telomeric functions of TRF2, a key telomere-capping protein, in muscle stem cells and define its role in regenerating myofibers following acute...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health under the Department of Health and Human Services, awarded $585,012 to Massachusetts General Hospital on June 2, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds research investigating the role of the C10ORF10/DEPP1 protein in skeletal muscle atrophy. The recipient will conduct three specific aims: defining the...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Arizona $578,565 on July 10, 2026, to investigate the role of skeletal myosin binding protein-C in distal arthrogryposis under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). Distal arthrogryposis is a genetic skeletal muscle disorder characterized by congenital joint contractures, muscle weakness, and reduced mobility with significant clinical morbidity. No...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Arizona $1,887,717 on July 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to decode the molecular mechanisms of nebulin, a giant actin-binding protein implicated in congenital myopathies. The award funds investigation of how dominant NEB gene variants involving large in-frame deletions—particularly the NEBD14-89 mutation—cause disease through altered...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Pennsylvania $2,063,666 on June 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate protein translation efficiency in T cell adaptation to human skin. The research addresses tissue-resident memory T cells (TRM) that persist in skin despite current immunosuppressive treatments and drive chronic inflammatory and autoimmune skin disease. The...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Pennsylvania $507,606 on June 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846, Assistance Listing Project Grant). The research investigates how mechanical loading activates focal adhesion kinase (FAK)-mediated mechanotransduction in tendon cells within their native extracellular matrix environment. The project builds on preliminary findings showing...
- The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Wisconsin System $164,000 on December 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to fund research into the role of the protein SKNAC in mechanically induced skeletal muscle growth. The research investigates signaling pathways that promote muscle mass preservation and growth in response to mechanical loading....
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $151,040 to The University of Texas Southwestern Medical Center on April 15, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop muscle-optimized non-viral gene editors for Duchenne muscular dystrophy. The project addresses limitations in lipid nanoparticle (LNP) delivery of CRISPR gene editing to skeletal muscle by designing gene editors that improve myonuclear...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Cincinnati Children's Hospital Medical Center $510,175 on August 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate the molecular mechanisms of skeletal muscle cell fusion. The research integrates biochemical, cellular, and genetic strategies to define the lipid pathways that enable myomaker-dependent lipid remodeling in myoblasts and establish the...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Pennsylvania $2.298 million on June 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds research into osteocyte peri-lacunar and canalicular remodeling mechanisms in maternal bone adaptation during pregnancy, lactation, and post-lactation phases. The project investigates how the female skeleton undergoes bone loss and microstructural...